IP Library › Granted Patent US 12,016,919
Granted Patent B2
US 12,016,919 · App. 16/616,999 · Granted Jun 25, 2024

Methods for manufacturing an adjuvant

Inventors: Pol Harvengt (Rixensart, BE); Philippe Jehoulet (Rixensart, BE); Loic Le Gourrierec (Rixensart, BE); Demostene Sifakakis (Rixensart, BE); Laurent Strodiot (Rixensart, BE)
Assignee: GLAXOSMITHKLINE BIOLOGICALS SA
A61K39/39B01F23/4105B01F25/4334B01F33/3017A61K2039/55555A61K2039/55572A61K2039/55577B01F23/4143B01F2101/22B01F2215/0431B01F2215/044B01F2215/045
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,016,919
App. No.
16/616,999
Granted
Jun 25, 2024
Kind
B2
Abstract

The present invention relates to compositions and methods for manufacturing an adjuvant comprising a saponin using a microfluidic device and to aspects thereof.

Claims (19)

1. A solution comprising a solvent and 100-170 mg/ml phosphatidylcholine lipid, wherein the solvent comprises 70-90% v/v ethanol and 10-30% v/v isopropyl alcohol.

2. The solution according to claim 1 , comprising 100-160 mg/ml phosphatidylcholine.

3. The solution according to claim 2 , comprising 120-140 mg/ml phosphatidylcholine.

4. The solution according to claim 1 , further comprising 20-50 mg/ml sterol.

5. The solution according to claim 4 , comprising 30-40 mg/ml of sterol.

6. The solution according to claim 4 , wherein the ratio of phosphatidylcholine to sterol is 3:1 to 5:1.

7. The solution according to claim 4 , wherein the sterol is cholesterol.

8. The solution according to claim 1 , further comprising a Toll-like receptor 4 (TLR4) agonist.

9. The solution according to claim 8 , wherein the TLR4 agonist is a lipopolysaccharide.

10. The solution according to claim 9 , wherein the lipopolysaccharide is 3-de-O-acylated monophosphoryl lipid A (3D-MPL).

11. The solution according to claim 8 , wherein the TLR4 agonist is present at a concentration of 4-12 mg/ml.

12. The solution according to claim 1 , wherein the solvent comprises 75-85% v/v ethanol.

13. The solution according to claim 1 , wherein the solvent comprises 15-25% v/v isopropanol.

14. The solution according to claim 1 , wherein the solvent comprises 78-82% v/v ethanol, and 18-22% v/v isopropyl alcohol.

15. The solution according to claim 1 , wherein the phosphatidylcholine lipid contains saturated unbranched acyl chains having 12-20 carbon atoms.

16. The solution according to claim 15 , wherein the lipid is dioleoyl phosphatidylcholine (DOPC).

17. A solution which consists essentially of a solvent and 100-160 mg/ml DOPC, 30-40 mg/ml cholesterol, 4-10 mg/ml TLR4 agonist, and wherein the solvent comprises 70-90% v/v ethanol and 10-30% v/v isopropyl alcohol.

18. The solution according to claim 17 wherein the TLR4 agonist is a lipopolysaccharide.

19. The solution according to claim 18 , wherein the lipopolysaccharide is 3D-MPL.

Continuity (2)
Provisional Application 62512352 · May 30, 2017
Related Publication 20210162042A1 · Jun 3, 2021
Cited By (1)
US 12,551,553